Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14

Benzinga · 2d ago
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.